GlassScriptPhysician profile
Lin Gong
NPI 1063483311
$16,957.81
in general payments reported to CMS, 2019-2025
42 companies · $2,895 in 2025
The $2,895 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,849 · 2020: $474 · 2021: $1,209 · 2022: $1,819 · 2023: $2,384 · 2024: $3,328 · 2025: $2,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,606.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,956.17 | 2019-2025 | Livdelzi, Vemlidy |
| Glaxosmithkline, LLC. | $1,374.41 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,306.99 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $946.85 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $930.45 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $820.11 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $814.59 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $731.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $625.57 | 2019-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Amarin Pharma, INC. | $620.57 | 2019-2022 | |
| Pfizer INC. | $517.28 | 2019-2025 | |
| Exact Sciences Corporation | $513.83 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $476.00 | 2023-2025 | |
| Lilly USA, LLC | $306.88 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $263.21 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Gong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.